Cyteir - About the company
Cyteir is a public company based in Cambridge (United States), founded in 2012. It operates as a Develops small molecules for the treatment of cancer and autoimmune diseases. Cyteir has raised $155M in funding from investors like Venrock, Celgene and RA Capital Management. The company has 3796 active competitors, including 1294 funded and 877 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Alnylam.
Company Details
Develops small molecules for the treatment of cancer and autoimmune diseases. The company's product pipeline includes CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters and CYT-0851 a combination with capecitabine and gemcitabine for patients with advanced ovarian cancer.
- Website
- cyteir.com
Key Metrics
Founded Year
2012
Location
Cambridge, United States
Stage
Public
Total Funding
$155M in 7 rounds
Latest Funding Round
Ranked
898th among 3796 active competitors
Employee Count
1 as on Sep 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Cyteir
Cyteir is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Cyteir Therapeutics, Inc. CIN: 1662244 , United States, Active | Jun 03, 2012 | - | 46 (As on Dec 31, 2022) | - |
Cyteir Therapeutics, Inc. CIN: 45-5429901 , United States, Active | - | 40 (As on Dec 31, 2021) | - |
Cyteir's IPO details
Cyteir got listed on Jun 18, 2021.
Click here to take a look at Cyteir's IPO in detail
Sign up to download Cyteir's company profile
Cyteir's funding and investors
Cyteir has raised a total funding of $155M over 7 rounds. Its first funding round was on Jul 15, 2014. Its latest funding round was a Post IPO round on Jun 22, 2021 for $*****. 1 investor participated in its latest round. Cyteir has 18 institutional investors.
Here is the list of recent funding rounds of Cyteir:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 22, 2021 | 5368595 | Post IPO | 8934797 | 6576311 | 5208617 | 4361503 |
Feb 11, 2021 | 7228972 | Series C | 2724220 | 8461181 | 9654773 | |
Oct 14, 2019 | 4089403 | Series B | 6084463 | 6585610 |
View details of Cyteir's funding rounds and investors
Cyteir's founders and board of directors
Founder? Claim ProfileCyteir's employee count trend
Cyteir has 1 employees as of Sep 26. Here is Cyteir's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Cyteir's Competitors and alternates
Top competitors of Cyteir include Jazz Pharmaceuticals, BeiGene and Alnylam. Here is the list of Top 10 competitors of Cyteir, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd | BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
4th | Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
5th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
6th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
7th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
8th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
9th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
898th | Cyteir 2012, Cambridge (United States), Public | Develops small molecules for the treatment of cancer and autoimmune diseases | $155M | 46/100 |
Looking for more details on Cyteir's competitors? Click here to see the top ones
Cyteir's Investments and acquisitions
Cyteir has made no investments or acquisitions yet.
Reports related to Cyteir
Here is the latest report on Cyteir's sector:
News related to Cyteir
•
•
•
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsTullahoma News•Mar 24, 2023•Cyteir
•
Cyteir Therapeutics Promotes David Gaiero to Chief Financial OfficerBusiness Wire•Feb 02, 2023•Cyteir, WAVE Life Sciences
•
Cyteir Therapeutics to prioritize development of ovarian cancer therapy, reduce workforceSeeking Alpha•Jan 20, 2023•Cyteir
•
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational HighlightsBusiness Wire•Nov 08, 2022•Cyteir
•
•
Cyteir pauses development of cancer med, funnels cash towards lead assetFierce Biotech•Aug 09, 2022•Cyteir
•
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational HighlightsBusiness Wire•Aug 09, 2022•Cyteir
•
Are you a Founder ?
FAQs about Cyteir
Explore our recently published companies
- Keyah Construction - 2003 founded, Unfunded company
- XIAMEN LILAI - China based, 1999 founded, Unfunded company
- XAUTOMATA TECHNOLOGY - Austria based, 2014 founded, Unfunded company
- RHE Grundbesitz - Berlin based, 2002 founded, Unfunded company
- ThimPress - Vietnam based, 2010 founded, Unfunded company
- Autopilot - Unfunded company